Celsion Corporation Announces Promising ThermoDox(R) Clinical Results in Primary Liver Cancer Were Published in Expert Opinion

COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, announced that promising Phase 1 ThermoDox clinical results in hepatocellular carcinoma (HCC) or primary liver cancer have been published in the peer-reviewed medical journal Expert Opinion on Pharmacology. The review article titled “Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer” was published in the February issue (Expert Opin. pharmacother. (2009)10(2):333-343).